• Share price
• Investor PDF
• Interims 2008 PDF

19 July 2007

Result of AGM

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, held its Annual General Meeting yesterday afternoon at which all resolutions were duly passed.

At the AGM, the Company’s Chairman, Dr William Potter, made the following comments: “As we reported at the time of our preliminary results, we are moving closer to EU regulatory approval of CSD500, which will be launched under the Durex® brand by our partner SSL International plc. Regulatory approval remains on track for Q4 of this year and we look forward to making the transition to a revenue generating business with a recurring royalty stream."

“Also, as mentioned at the time of our preliminary results, we have been encouraged by the level of interest from potential licensing partners in MED2002, our OTC treatment for erectile dysfunction. Out-licensing negotiations are continuing and we remain confident that a licensing partner will be secured on attractive commercial terms in due course."

“We continue to make progress on our earlier-stage portfolio and in seeking new applications for our novel drug delivery technology, DermaSys®”

In accordance with AIM Rule 17, Futura Medical notes the transfer of ordinary shares in the Company by the following Directors, though there has been no material change to the total shareholdings of any of the Directors:

James H Barder, Chief Executive

1 Feb 05: Transfer of 236,997 Futura shares from paper certificate (in the name of James Barder) into Carr Sheppards nominee account (Ferlim Nominees) for the account of James Barder

4 Feb 05: Transfer of 250,000 Futura shares from paper certificate (in the name of Charlotte Barder) into Carr Sheppards nominee account (Ferlim Nominees) for the account of Charlotte Barder

23 Feb 05: Sale of 11,000 Futura shares from James Barder and purchase of 11,000 Futura shares into Sippdeal Trustees Ltd for the account of James Barder

26 Feb 07: Sale of 74,500 Futura shares from James Barder and purchase of 74,500 Futura shares into Sippdeal Trustees Ltd for the account of James Barder

David B Davies, Product Development Director

13 July 2005: Sale of 15,152 Futura shares from David Davies and purchase of 15,152 Futura shares into Hargreaves Lansdown Vantage SIPP for the account of David Davies

26 Mar 07: Sale of 61,084 Futura shares from David Davies and purchase of 60,381 Futura shares into Hargreaves Lansdown Vantage SIPP for the account of David Davies.  The balance of 703 Futura shares not purchased in to the Hargreaves Lansdown Vantage SIPP covered dealing costs associated with the transaction.

 

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare.  The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.  

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.co.uk

Site map | Contact us | By using the website, you are deemed to have accepted the terms of the disclaimer.

© and Database Right: Futura Medical Plc 2004 - 2008. All rights reserved.